[1] Tanaka, M., Ma, E., Tanaka, H., Ioka, A., Nakahara, T. and Takahashi, H. (2012) Trends of Stomach Cancer Mortality in Eastern Asia in 1950-2004: Comparative Study of Japan, Hong Kong and Singapore Using Age, Period and Cohort Analysis. International Journal of Cancer, 130, 930-936.
http://dx.doi.org/10.1002/ijc.26080
[2] Boku, N., Yamamoto, S., Fukuda, H., Shirao, K., Doi, T., Sawaki, A., Koizumi, W., Saito, H., Yamaguchi, K., Takiuchi, H., Nasu, J. and Ohtsu, A. (2009) Gastrointestinal Oncology Study Group of the Japan Clinical Oncology G: Fluorouracil versus Combination of Irinotecan plus Cisplatin versus S-1 in Metastatic Gastric Cancer: A Randomised Phase 3 Study. The Lancet Oncology, 10, 1063-1069.
http://dx.doi.org/10.1016/S1470-2045(09)70259-1
[3] Koizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., Miyashita, K., Nishizaki, T., Kobayashi, O., Takiyama, W., Toh, Y., Nagaie, T., Takagi, S., Yamamura, Y., Yanaoka, K., Orita, H. and Takeuchi, M. (2008) S-1 plus Cisplatin versus S-1 Alone for First-Line Treatment of Advanced Gastric Cancer (Spirits Trial): A Phase III Trial. The Lancet Oncology, 9, 215-221.
http://dx.doi.org/10.1016/S1470-2045(08)70035-4
[4] Waddell, T., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., Arnold, D., European Society for Medical Oncology (ESMO), European Society of Surgical Oncology (ESSO) and European Society of Radiotherapy and Oncology (ESTRO) (2013) Gastric Cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 24, 57-63.
http://dx.doi.org/10.1093/annonc/mdt344
[5] Mor, V., Stalker, M.Z., Gralla, R., Scher, H.I., Cimma, C., Park, D., Flaherty, A.M., Kiss, M., Nelson, P., Laliberte, L., et al. (1988) Day Hospital as an Alternative to Inpatient Care for Cancer Patients: A Random Assignment Trial. Journal of Clinical Epidemiology, 41, 771-785.
http://dx.doi.org/10.1016/0895-4356(88)90164-3
[6] Horinouchi, H., Kubota, K., Itani, H., Taniyama, T.K., Nakamichi, S., Wakui, H., Kanda, S., Nokihara, H., Yamamoto, N., Sekine, I. and Tamura, T. (2013) Short Hydration in Chemotherapy Containing Cisplatin (>/=75 mg/m2) for Patients with Lung Cancer: A Prospective Study. Japanese Journal of Clinical Oncology, 43, 1105-1109.
http://dx.doi.org/10.1093/jjco/hyt122
[7] Ouchi, A., Asano, M., Aono, K., Watanabe, T. and Kato, T. (2014) Comparison of Short and Continuous Hydration Regimen in Chemotherapy Containing Intermediate- to High-Dose Cisplatin. Journal of Oncology, 2014, Article ID: 767652.
http://dx.doi.org/10.1155/2014/767652
[8] Okazaki, S., Nakajima, T.E., Hashimoto, J., Yamamoto, S., Takahari, D., Kato, K., Hamaguchi, T., Yamada, Y., Shimada, Y. and Tamura, K. (2013) A Feasibility Study of Outpatient Chemotherapy with s-1 + Cisplatin in Patients with Advanced Gastric Cancer. Gastric Cancer, 16, 41-47.
http://dx.doi.org/10.1007/s10120-012-0139-4
[9] Satake, H., Tsuji, A., Kotake, T. and Fujita, M. (2014) Feasibility of Outpatient Chemotherapy with S-1 and Cisplatin for Gastric Cancer. Journal of Cancer Therapy, 5, 759-765.
http://dx.doi.org/10.4236/jct.2014.58084
[10] Kitazaki, T., Fukuda, Y., Fukahori, S., Oyanagi, K., Soda, H., Nakamura, Y. and Kohno, S. (2015) Usefulness of antiemetic Therapy with Aprepitant, Palonosetron, and Dexamethasone for Lung Cancer Patients on Cisplatin-Based or Carboplatin-Based Chemotherapy. Supportive Care in Cancer, 23, 185-190.
http://dx.doi.org/10.1007/s00520-014-2339-4
[11] Longo, F., Mansueto, G., Lapadula, V., Stumbo, L., Del Bene, G., Adua, D., De Filippis, L., Bonizzoni, E. and Quadrini, S. (2012) Combination of Aprepitant, Palonosetron and Dexamethasone as Antiemetic Prophylaxis in Lung Cancer Patients Receiving Multiple Cycles of Cisplatin-Based Chemotherapy. International Journal of Clinical Practice, 66, 753-757.
http://dx.doi.org/10.1111/j.1742-1241.2012.02969.x